Cerebral MR Spectroscopy Evaluation of the Neuroprotective Effects of Lithium and Olanzapine in Bipolar Affective Disorder Patients

Basit Öğe Kaydı
dc.authoridozcan, abdulcemal/0000-0002-6759-7556
dc.authoridUnal, Suheyla/0000-0003-3266-6256
dc.authoridUnal, Suheyla/0000-0003-3266-6256
dc.authoridErkorkmaz, Ünal/0000-0002-8497-4704
dc.authoridKarlıdağ, Rifat/0000-0002-3650-0774
dc.authorwosidozcan, abdulcemal/B-1348-2008
dc.authorwosidUnal, Suheyla/HJH-7559-2023
dc.authorwosidkarlıdağ, rıfat/AAB-4255-2021
dc.authorwosidUnal, Suheyla/JVO-8367-2024
dc.authorwosidUnal, Suheyla/AAS-2388-2020
dc.authorwosidErkorkmaz, Ünal/AAA-4241-2022
dc.authorwosidSaraç, Kaya/ABI-1091-2020
dc.contributor.authorCumurcu, Birgul Elbozan
dc.contributor.authorKarlidag, Rifat
dc.contributor.authorSarac, Kaya
dc.contributor.authorUnal, Suheyla
dc.contributor.authorOzcan, Cemal
dc.contributor.authorErkorkmaz, Unal
dc.date.accessioned2024-08-04T20:31:01Z
dc.date.available2024-08-04T20:31:01Z
dc.date.issued2008
dc.departmentİnönü Üniversitesien_US
dc.description.abstractAim: We used the NAA measurements obtained by cerebral magnetic resonance spectroscopy to evaluate the neuroprotective effects of lithium and olanzapine in bipolar affective disorder patients in remissions. Methods:Ten bipolar affective disorder patients on lithium treatment for the last six years and who had not experienced a manic or depressive attack for the last three years and were followed up at the psychiatry outpatients department were included in the study. The patients were evaluated while on lithium, 14 days after lithium was stopped and at the end of the 411 week following olanzapine initiation, for a total of three times. Each evaluation consisted of a psychiatric interview, the Hamilton Depression Rating Scale (HDRS) and the Bech-Rafaelson Mania Scale (BRMS) in addition to MR spectroscopy imaging. Results: The cases were compared with a control group consisting of 10 age- and sex-matched healthy subjects. We measured the N-acetyl aspartate (NAA) peak quantitatively in the right dorsolateral prefrontal cortex (DLPF) and left hippocampus areas on MR spectroscopy and checked the ratio to the creatine (Cr) peak. The values from all three imaging studies were compared with each other and with the control subjects. Conclusions: There was no statistically significant difference between the NAA/Cr ratios of the patients receiving lithium, those not on medications or those receiving olanzapine and the healthy subjects. We did not observe any change in cerebral NAA levels following lithium and olanzapine treatment in bipolar affective disorder patients in remission.en_US
dc.identifier.endpage32en_US
dc.identifier.issn0941-9500
dc.identifier.issue1en_US
dc.identifier.scopus2-s2.0-54949138779en_US
dc.identifier.scopusqualityQ3en_US
dc.identifier.startpage27en_US
dc.identifier.urihttps://hdl.handle.net/11616/94681
dc.identifier.volume15en_US
dc.identifier.wosWOS:000207501600006en_US
dc.identifier.wosqualityQ4en_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.indekslendigikaynakScopusen_US
dc.language.isoenen_US
dc.publisherUniversitatsverlag Ulm Gmbhen_US
dc.relation.ispartofNeurology Psychiatry and Brain Researchen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.subjectBipolar affective disorderen_US
dc.subjectlithiumen_US
dc.subjectolanzapineen_US
dc.subjectneuroprotective effecten_US
dc.subjectN-acetyl aspartateen_US
dc.titleCerebral MR Spectroscopy Evaluation of the Neuroprotective Effects of Lithium and Olanzapine in Bipolar Affective Disorder Patientsen_US
dc.typeArticleen_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu